Kazufumi Kobayashi1, Hitoshi Maruyama2, Soichiro Kiyono1, Sadahisa Ogasawara1, Eiichiro Suzuki1, Yoshihiko Ooka1, Tetsuhiro Chiba1, Naoya Kato1, Tadashi Yamaguchi3. 1. Department of Gastroenterology, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan. 2. Department of Gastroenterology, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670, Japan. maru-cib@umin.ac.jp. 3. Center for Frontier Medical Engineering, Chiba University, 1-33, Yayoi-cho, Inage-ku, Chiba, 263-8522, Japan.
Abstract
BACKGROUND: To propose an ultrasound-based parameter for the diagnosis of muscle mass loss (MML) in cirrhosis. METHODS: This is an IRB-approved cross-sectional study (October 2013 to January 2017) with written informed consent including 357 subjects-234 cirrhosis and 123 controls. MML was diagnosed using the skeletal muscle index at the L3 level (L3-SMI) on computed tomography (CT). Transcutaneous ultrasound was used to demonstrate a cross section of the right iliopsoas muscle, and the iliopsoas muscle index (IP index) was defined by the iliopsoas muscle area/height2 (mm2/m2). Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic ability of IP index for MML. RESULTS: The iliopsoas muscle was detected in all subjects. The IP index was lower in cirrhosis than in controls: males (211.2 ± 73.8 vs. 295.5 ± 139.4, P < 0.0001) and females (200.2 ± 72.5 vs. 284.4 ± 112.4, P < 0.0001). L3-SMI and IP index showed correlations in males (r = 0.699, P < 0.0001) and in females (r = 0.707, P < 0.0001). Independent factors for MML by multivariate analysis were body mass index and IP index in both males and females. Sensitivity, specificity, and area under the ROC curve by IP index to detect MML were 79.5%, 73.1%, and 0.835, respectively, with the best cut-off value of 189.2 for males, and 84.6%, 78.8%, and 0.874, respectively, with the best cut-off value of 180.6 for females. CONCLUSIONS: Using transcutaneous ultrasound, the IP index may be a valuable diagnostic parameter for MML in cirrhosis.
BACKGROUND: To propose an ultrasound-based parameter for the diagnosis of muscle mass loss (MML) in cirrhosis. METHODS: This is an IRB-approved cross-sectional study (October 2013 to January 2017) with written informed consent including 357 subjects-234 cirrhosis and 123 controls. MML was diagnosed using the skeletal muscle index at the L3 level (L3-SMI) on computed tomography (CT). Transcutaneous ultrasound was used to demonstrate a cross section of the right iliopsoas muscle, and the iliopsoas muscle index (IP index) was defined by the iliopsoas muscle area/height2 (mm2/m2). Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic ability of IP index for MML. RESULTS: The iliopsoas muscle was detected in all subjects. The IP index was lower in cirrhosis than in controls: males (211.2 ± 73.8 vs. 295.5 ± 139.4, P < 0.0001) and females (200.2 ± 72.5 vs. 284.4 ± 112.4, P < 0.0001). L3-SMI and IP index showed correlations in males (r = 0.699, P < 0.0001) and in females (r = 0.707, P < 0.0001). Independent factors for MML by multivariate analysis were body mass index and IP index in both males and females. Sensitivity, specificity, and area under the ROC curve by IP index to detect MML were 79.5%, 73.1%, and 0.835, respectively, with the best cut-off value of 189.2 for males, and 84.6%, 78.8%, and 0.874, respectively, with the best cut-off value of 180.6 for females. CONCLUSIONS: Using transcutaneous ultrasound, the IP index may be a valuable diagnostic parameter for MML in cirrhosis.
Entities:
Keywords:
Cirrhosis; Muscle mass loss; Non-invasive diagnosis; Ultrasound
Authors: Puneeta Tandon; Michael Ney; Ivana Irwin; Mang M Ma; Leah Gramlich; Vincent G Bain; Nina Esfandiari; Vickie Baracos; Aldo J Montano-Loza; Robert P Myers Journal: Liver Transpl Date: 2012-10 Impact factor: 5.799
Authors: F Oberti; E Valsesia; C Pilette; M C Rousselet; P Bedossa; C Aubé; Y Gallois; H Rifflet; M Y Maïga; D Penneau-Fontbonne; P Calès Journal: Gastroenterology Date: 1997-11 Impact factor: 22.682
Authors: Aldo J Montano-Loza; Judith Meza-Junco; Carla M M Prado; Jessica R Lieffers; Vickie E Baracos; Vincent G Bain; Michael B Sawyer Journal: Clin Gastroenterol Hepatol Date: 2011-09-03 Impact factor: 11.382
Authors: Judith Meza-Junco; Aldo J Montano-Loza; Vickie E Baracos; Carla M M Prado; Vincent G Bain; Crystal Beaumont; Nina Esfandiari; Jessica R Lieffers; Michael B Sawyer Journal: J Clin Gastroenterol Date: 2013 Nov-Dec Impact factor: 3.062
Authors: Puneeta Tandon; Gavin Low; Marina Mourtzakis; Laura Zenith; Robert P Myers; Juan G Abraldes; Abdel Aziz M Shaheen; Hina Qamar; Nadia Mansoor; Michelle Carbonneau; Kathleen Ismond; Sumeer Mann; Alshimaa Alaboudy; Mang Ma Journal: Clin Gastroenterol Hepatol Date: 2016-05-14 Impact factor: 11.382
Authors: Wolfgang M Kremer; Christian Labenz; Robert Kuchen; Ingo Sagoschen; Marc Bodenstein; Oliver Schreiner; Marcus A Wörns; Visvakanth Sivanathan; Arndt Weinmann; Peter R Galle; Martin F Sprinzl Journal: J Cachexia Sarcopenia Muscle Date: 2021-12-08 Impact factor: 12.910
Authors: Jennifer C Lai; Puneeta Tandon; William Bernal; Elliot B Tapper; Udeme Ekong; Srinivasan Dasarathy; Elizabeth J Carey Journal: Hepatology Date: 2021-09 Impact factor: 17.298
Authors: Martijn V Verhagen; Stef Levolger; Jan Binne Hulshoff; Maureen J M Werner; Hubert P J van der Doef; Alain R Viddeleer; Ruben H de Kleine; Robbert J de Haas Journal: Liver Transpl Date: 2021-08-01 Impact factor: 6.112